Helus Pharma Inc. Common Stock
HELP
86 hedge funds and large institutions have $23.5M invested in Helus Pharma Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 18 increasing their positions, 8 reducing their positions, and 6 closing their positions.
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
125% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 8
89% more capital invested
Capital invested by funds: $12.4M → $23.5M (+$11M)
23% more funds holding
Funds holding: 70 → 86 (+16)
4.13% more ownership
Funds ownership: 9.98% → 14.1% (+4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.44M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$4.37M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.78M |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$2.56M |
| 5 |
PP
PDS Planning
Dublin,
Ohio
|
+$565K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$198K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$44.7K |
| 3 |
WLPWM
Walled Lake Planning & Wealth Management
Winnetka,
Illinois
|
-$30.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$12.6K |
| 5 |
Legacy Financial Group (Iowa)
Des Moines,
Iowa
|
-$12K |
HELP Hedge Fund Activity: Q4 2023 in Review
86 of the 6,872 institutional investors tracked by Wall St. Rank reported a position in Helus Pharma Inc. Common Stock (HELP) for Q4 2023, worth a combined $23.5M — up 89% from $12.4M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new HELP positions and 6 closed out — a net gain of 17 holders — while 18 added to existing stakes and 8 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $5.44M. The largest seller was Jane Street, exiting entirely with an estimated $198K sold.
- 86 institutional investors held Helus Pharma Inc. Common Stock (HELP) as of Q4 2023, up from 70 in Q3 2023.
- Funds reported $23.5M of Helus Pharma Inc. Common Stock stock for Q4 2023, up 89% quarter-over-quarter.
- 23 funds opened new Helus Pharma Inc. Common Stock positions in Q4 2023 and 6 closed out, a net change of +17 holders.
- The largest Helus Pharma Inc. Common Stock buyer in Q4 2023 was Point72 Asset Management, an estimated $5.44M added.
- The largest Helus Pharma Inc. Common Stock seller in Q4 2023 was Jane Street, an estimated $198K sold.
Based on aggregated 13F filings for Q4 2023.